studies, he wrote, "have failed to change the practice of breast cancer prevention among women and their [doctors] , perhaps because of the side effects of these drugs".
The scientists leading the trial at the National Surgical Adjuvant Breast and Bowel Project, based in Pittsburgh, Pennsylvania, protested vehemently, and accused Niederhuber of "acting unilaterally". On 20 July, they hand-delivered a 13-page appeal to Zerhouni, asking him to intervene. Last week they said, "we've had some very positive interactions" with Zerhouni's office, and they are hopeful of meeting him this month.
The appeal has drawn media attention in the United States, and in a recent editorial The Lancet labelled Niederhuber's actions "troubling" and called for an investigation (Lancet 369, 2134; 2007) .
But Bruce Chabner of Massachusetts General Hospital, who chaired Niederhuber's ad hoc committee, says that the NIH's frozen budget has forced Niederhuber to make tough fiscal choices. He adds that the panel was strongly influenced by the fact that letrozole, made by Novartis, goes off-patent in 2011. "Was it worth spending millions on a trial that might never result in a drug being used for this indication?" he asks. "We thought it likely it wasn't. " 
